Butterfield Lisa H, Ribas Antoni, Potter Douglas M, Economou James S
Department of Medicine, Surgery and Immunology University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Cancer Immunol Immunother. 2007 Dec;56(12):1931-43. doi: 10.1007/s00262-007-0337-9. Epub 2007 May 24.
We are investigating the use of Alpha Fetoprotein (AFP) as a tumor rejection antigen for hepatocellular carcinoma (HCC). We recently completed vaccination of 10 AFP+/HLA-A2.1+ HCC subjects with AFP peptide-pulsed autologous dendritic cells (DC). There were increased frequencies of circulating AFP-specific T cells and of IFNgamma-producing AFP-specific T cells after vaccination. In order to better understand the lack of association between immune response and clinical response, we have examined additional aspects of the AFP immune response in patients. Here, we have characterized the cell surface phenotype of circulating AFP tetramer-positive CD8 T cells and assessed AFP-specific CD4 function. Before vaccination, HCC subjects had increased frequencies of circulating AFP-specific CD8 T cells with a range of naïve, effector, central and effector memory phenotypes. Several patients had up-regulated activation markers. A subset of patients was assessed for phenotypic changes pre- and post-vaccination, and evidence for complete differentiation to effector or memory phenotype was lacking. CD8 phenotypic and cytokine responses did not correlate with level of patient serum AFP antigen (between 74 and 463,040 ng/ml). Assessment of CD4+ T cell responses by ELISPOT and multi-cytokine assay did not identify any spontaneous CD4 T cell responses to this secreted protein. These data indicate that there is an expanded pool of partially differentiated AFP-specific CD8 T cells in many of these HCC subjects, but that these cells are largely non-functional, and that a detectable CD4 T cell response to this secreted oncofetal antigen is lacking.
我们正在研究将甲胎蛋白(AFP)用作肝细胞癌(HCC)的肿瘤排斥抗原。我们最近完成了对10名AFP阳性/HLA-A2.1阳性的HCC患者用AFP肽脉冲自体树突状细胞(DC)进行的疫苗接种。接种后,循环中AFP特异性T细胞以及产生IFNγ的AFP特异性T细胞的频率增加。为了更好地理解免疫反应与临床反应之间缺乏关联的原因,我们研究了患者AFP免疫反应的其他方面。在此,我们对循环中AFP四聚体阳性CD8 T细胞的细胞表面表型进行了特征分析,并评估了AFP特异性CD4功能。在接种疫苗前,HCC患者循环中具有一系列幼稚、效应、中枢和效应记忆表型的AFP特异性CD8 T细胞频率增加。几名患者的活化标志物上调。对一部分患者在接种疫苗前后的表型变化进行了评估,缺乏完全分化为效应或记忆表型的证据。CD8表型和细胞因子反应与患者血清AFP抗原水平(74至463,040 ng/ml之间)无关。通过ELISPOT和多细胞因子检测对CD4 + T细胞反应进行评估,未发现对这种分泌蛋白有任何自发的CD4 T细胞反应。这些数据表明,在许多此类HCC患者中存在部分分化的AFP特异性CD8 T细胞扩大池,但这些细胞大多无功能,并且缺乏对这种分泌的癌胚抗原有可检测到的CD4 T细胞反应。